3 Reasons Behind Exelixis Stock's Big Bounce

After experiencing a dismal September and sliding quite a bit over the last few weeks after a rebound, Exelixis (NASDAQ: EXEL) stock enjoyed a big bounce on Thursday. The biotech announced its third-quarter results after the market closed on the prior day. And those results were very good, with Exelixis reporting 126% year-over-year revenue growth and trouncing Wall Street earnings estimates.

Obviously, the biotech's third-quarter performance generated plenty of enthusiasm among investors. There's more to the story, though. Here are three underlying reasons behind Exelixis stock's resurgence. (Quotes courtesy of S&P Global Market Intelligence.)

Image source: Getty Images.

Source: Fool.com